Ertapenem

Ertapenem

Error creating thumbnail: File missing
Clinical data
ATC code	J01DH03 (WHO)
Identifiers
IUPAC name 3-[5-[(3-carboxyphenyl) carbamoyl]pyrrolidin-3-yl] sulfanyl-7-(1-hydroxyethyl)- 2-methyl- 6-oxo-5-azabicyclo[3.2.0] hept-3-ene-4-carboxylic acid
CAS Number	153832-46-3
PubChem CID	150610
DrugBank	APRD00952
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H25N3O7S
Molar mass	475.516 g/mol

WikiDoc Resources for Ertapenem
Articles
Most recent articles on Ertapenem Most cited articles on Ertapenem Review articles on Ertapenem Articles on Ertapenem in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ertapenem Images of Ertapenem Photos of Ertapenem Podcasts & MP3s on Ertapenem Videos on Ertapenem
Evidence Based Medicine
Cochrane Collaboration on Ertapenem Bandolier on Ertapenem TRIP on Ertapenem
Clinical Trials
Ongoing Trials on Ertapenem at Clinical Trials.gov Trial results on Ertapenem Clinical Trials on Ertapenem at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ertapenem NICE Guidance on Ertapenem NHS PRODIGY Guidance FDA on Ertapenem CDC on Ertapenem
Books
Books on Ertapenem
News
Ertapenem in the news Be alerted to news on Ertapenem News trends on Ertapenem
Commentary
Blogs on Ertapenem
Definitions
Definitions of Ertapenem
Patient Resources / Community
Patient resources on Ertapenem Discussion groups on Ertapenem Patient Handouts on Ertapenem Directions to Hospitals Treating Ertapenem Risk calculators and risk factors for Ertapenem
Healthcare Provider Resources
Symptoms of Ertapenem Causes & Risk Factors for Ertapenem Diagnostic studies for Ertapenem Treatment of Ertapenem
Continuing Medical Education (CME)
CME Programs on Ertapenem
International
Ertapenem en Espanol Ertapenem en Francais
Business
Ertapenem in the Marketplace Patents on Ertapenem
Experimental / Informatics
List of terms related to Ertapenem

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz®. It is structurally very similar to meropenem in that it possess a 1-β-methyl group.

Indications

Ertapenem has been designed to be effective against Gram negative bacteria. It is not active against MRSA, ampicillin-resistant enterococci, Pseudomonas aeruginosa or Acinetobacter species. Ertapenem also has clinically useful activity against anaerobic bacteria.

Ertapenem is marketed by Merck as a first-line treatment for community-acquired infections. It should not be used as empirical treatment for hospital-acquired infections because of its lack of activity against Pseudomonas aeruginosa. In practice, it is reserved primarily for use against ESBL-producing and high level AmpC-producing Gram-negative bacteria.

Dosage

Ertapenem is dosed as 1g given by intravenous injection over 30 minutes, or 1g diluted with 3.2ml of 1% lidocaine given intramuscularly. There is no oral preparation of ertapenem available. Ertapenem cannot be mixed with glucose.

The marketing slogan for ertapenem is "The Power of One", because the dose is one gram, once a day.

Pharmacology

Unlike imipenem and meropenem, ertapenem is highly protein bound, which explains its long half life (4 hours).

Ertapenem is excreted primarily (80%) by the kidneys. Metabolism by the liver is not clinically important and does not affect dosing.

Patients on haemodialysis should be given ertapenem at least 6 hours before dialysis. If it is given less than six hours before dialysis, then the patient should be given an additional dose of 150mg IV after dialysis. Ideally, patients on haemodialysis should be given ertapenem immediately following dialysis.

Resistance

Acquired resistance to ertapenem is usually mediated by up-regulation of efflux mechanisms and by the selection of porin-deficient mutants. Organisms that produce a metallo-β-lactamase are innately immune to ertapenem (as well as all carbapenems) (Reference needed).

Side effects

There are few adverse effects of ertapenem. The only absolute contra-indication is a previous anaphylactic reaction to ertapenem or other β-lactam antibiotic. There are no studies done in pregnant women, so the manufacturers cannot comment on its safety in pregnancy. In 2006, Ertapenem is now approved for pediatric use in certain infections. Ertapenem is not recommended for children under 3 months of age and children with meningitis.

Use of all antibiotics is associated with increased rates of resistance (although carbapenem resistance is currently rare). There is particular worry that although ertapenem has no clinically useful activity against Pseudomonas aeruginosa, widespread use of ertapenem could still lead to increased carbapenem resistance in Pseudomonas (Livermore et al. 2005).

Like many antibiotics, Clostridium difficile colitis has been associated with its use.

References

• Livermore DM, Mushtaq S, Warner M (2005). "Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems". J Antimicrob Chemother. 55 (3): 306&ndash, 311.CS1 maint: Multiple names: authors list (link)